tiprankstipranks
Advertisement
Advertisement
TG Therapeutics Earnings Call Signals BRIUMVI Surge
PremiumCompany AnnouncementsTG Therapeutics Earnings Call Signals BRIUMVI Surge
18d ago
Briumvi’s Rapid Commercial Momentum and Upward Sales Guidance Underpin Bancroft’s Buy Rating
Premium
Ratings
Briumvi’s Rapid Commercial Momentum and Upward Sales Guidance Underpin Bancroft’s Buy Rating
19d ago
TG Therapeutics falls -10.6%
Premium
The Fly
TG Therapeutics falls -10.6%
20d ago
TG Therapeutics price target raised to $86 from $55 at B. Riley
PremiumThe FlyTG Therapeutics price target raised to $86 from $55 at B. Riley
27d ago
Analyst Tara Bancroft Raises TG Therapeutics Price Target to $75 on Strong Long-Term Briumvi Growth Outlook
Premium
Ratings
Analyst Tara Bancroft Raises TG Therapeutics Price Target to $75 on Strong Long-Term Briumvi Growth Outlook
1M ago
TG Therapeutics Targets Myasthenia Gravis Growth With New BRIUMVI Trial
Premium
Company Announcements
TG Therapeutics Targets Myasthenia Gravis Growth With New BRIUMVI Trial
1M ago
TG Therapeutics Shareholders Reject Executive Compensation at Meeting
PremiumCompany AnnouncementsTG Therapeutics Shareholders Reject Executive Compensation at Meeting
2M ago
TG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged
Premium
Ratings
TG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged
2M ago
TG Therapeutics announces Briumvi data, initiates clinical trial
Premium
The Fly
TG Therapeutics announces Briumvi data, initiates clinical trial
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100